Medical White Papers
Presented by
Source: Ionicon Analytik Ges.m.b.H.  Mar 11, 2019
Over the last few years, a developing field of research has emerged in breath gas analysis of volatile organic compounds (VOCs). This technique is non-invasive and has a number of possible applications, including monitoring of metabolic processes, study of pharmacokinetics, screening for disease biomarkers and drug testing. Advantages of IONICON PTR-TOFMS The detection limits and linearity ran...
Source: Albumedix Ltd  Feb 17, 2019
Overcoming Formulation Challenges of Biotherapeutics The increasing study of vaccines and biotherapeutics gives promise for improvement of treatments against various diseases. While protein engineering has shown a great level of growth, several of these therapies persist in the face of ex vivo uncertainty challenges (both physical and chemical instability) which are a source of dosage form inadequ...
Author : Mitchel.L .Zoler, MDedge News  Jan 14, 2019
AHA 2019 CONFERENCE COVERAGE   REPORTING FROM THE AHA SCIENTIFIC SESSIONS CHICAGO – When the first results from a large trial that showed profound and unexpected benefits for preventing heart failure hospitalizations associated with use of the antihyperglycemic sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin came out – a little over 3 years ago – the gen...
EKF Diagnostics  Jan 01, 2019
Diabetes, also known as diabetes mellitus, is a common metabolic disease that is characterized by frequent sessions of uncontrolled high blood sugar or hyperglycaemia caused by poor insulin production or increased resistance to insulin. The World Health Organization (WHO) has reported that 8.5% of the global population was affected by diabetes in 2014, or roughly 422 million people.1 Diabetes is ...
Source: PAREXEL  Nov 12, 2018
After two chimeric antigen receptor (CAR) T-cell therapies won FDA approval in 2017 to treat children and young adults with acute lymphoblastic leukemia (ALL) and adults with diffuse large B-cell lymphoma, the American Society of Clinical Oncology hailed CAR T-Cell Immunotherapy as the Advance of the Year.1 Complete remission/response rates in clinical trials for these medicines (both targeting th...